| Authors: |
Tiedt R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., King FJ; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Stamm C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Niederst MJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com., Delach S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Zumstein-Mecker S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Meltzer J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Mulford IJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Labrot E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Engstler BS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Baltschukat S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Kerr G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Golji J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Wyss D; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Ainscow E; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Sellers WR; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Barretina J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Porta DG; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland. |
